| Journal | CNS & neurological disorders drug targets |
| Study Type | Clinical Study |
| Population | Human participants |
This review synthesizes evidence on CBD’s dual impact on seizure control and motor function in epilepsy, addressing a critical gap since movement disorders frequently complicate epilepsy management. Understanding CBD’s motor safety profile is essential given that many antiepileptic drugs cause significant locomotor side effects.
This comprehensive review analyzed animal and human studies of CBD in epilepsy, incorporating network pharmacology and molecular modeling approaches. The authors found that CBD demonstrates minimal to no adverse effects on motor function while showing promise for seizure control through prolonged seizure onset times and reduced seizure severity. The review reinforces CBD’s established low toxicity profile and good tolerability. However, the summary appears incomplete and lacks specific details about study methodology, patient populations, or quantitative outcomes.
“I appreciate seeing motor outcomes specifically addressed, as this is often overlooked in epilepsy research despite being clinically crucial. However, without access to the complete methodology and quantitative results, I cannot assess the strength of these conclusions for clinical decision-making.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
This study item was assembled from normalized source metadata and pipeline scoring.